Susan M. Domchek

Oncology

3400 Civic Center Boulevard
West Pavilion, 3rd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 369 publications

Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review.

Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review.

Journal: AJR. American journal of roentgenology

Published: May 06, 2026

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: April 30, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Journal: Cancer research communications

Published: March 25, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Journal: Cancer research communications

Published: March 25, 2026

A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study).

A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study).

Journal: BMC medical ethics

Published: March 04, 2026

Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.

Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.

Journal: International journal of cancer

Published: March 03, 2026

Cancer During Pregnancy: Navigating Clinical and Research Challenges.

Cancer During Pregnancy: Navigating Clinical and Research Challenges.

Journal: Current oncology (Toronto, Ont.)

Published: March 03, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.

Journal: eLife

Published: February 03, 2026

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 28, 2026

High-throughput mapping of 6,888 RAD51D variants identifies distinct biochemical functions needed for homologous recombination and olaparib response.

High-throughput mapping of 6,888 RAD51D variants identifies distinct biochemical functions needed for homologous recombination and olaparib response.

Journal: bioRxiv : the preprint server for biology

Published: January 16, 2026

Showing 1-12 of 369

Last Updated: 09/26/2026